SCP
IVA

SymBiosis Capital Partners’s Inventiva IVA Stock Holding History

SymBiosis Capital Partners’s Portfolio IVA Stock Details IVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Sell
2,354,000
-246,000
-9% -$1.5M 24.76% 2
2025
Q4 		$12.1M Buy
+2,600,000
New +$12.1M 11.04% 5

Other funds holding IVA

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM

SymBiosis Capital Partners's IVA Position: Q1 2026 in Review

SymBiosis Capital Partners reduced its Inventiva (IVA) stake by 9.5% in Q1 2026, selling an estimated $1.5M and leaving 2,354,000 shares worth $13.1M. The position accounts for 24.76% of the portfolio, ranked #2.

SymBiosis Capital Partners first reported a position in IVA in Q4 2025 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold IVA as of Q1 2026.

  • SymBiosis Capital Partners held 2,354,000 shares of Inventiva worth $13.1M as of Q1 2026.
  • SymBiosis Capital Partners sold 246,000 Inventiva shares in Q1 2026, an estimated $1.5M.
  • Inventiva made up 24.76% of SymBiosis Capital Partners's portfolio in Q1 2026, its #2 holding.
  • SymBiosis Capital Partners first reported a position in Inventiva in Q4 2025 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Inventiva as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.